Perspective Therapeutics (CATX) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 29.1% versus a loss of 60.3%. Over five years, CATX leads with a -60.3% price change compared with -85.9% for FULC. Perspective Therapeutics is the larger company by market cap ($280.8 million vs $280.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | FULC |
|---|---|---|
| Share price | $2.46 | $3.67 |
| Market cap | $280.81M | $280.01M |
| 1-day change | +4.24% | -0.54% |
| YTD return | -10.55% | -67.55% |
| 1-year return | -29.11% | -60.28% |
| 5-year return | -60.32% | -85.88% |
| EPS (TTM) | $-1.33 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $15.74 |
| 52-week low | $1.96 | $2.83 |
| Distance from 52-week high | -60.06% | -76.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +399.59% | 0.00% |
| Average volume | 1.67M | 1.53M |
| Shares outstanding | 114.15M | 76.30M |
| Employees | 163 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed FULC by 31.2 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CATX vs FULC FAQ
Which is bigger, Perspective Therapeutics or Fulcrum Therapeutics?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $280.81M compared with $280.01M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, CATX or FULC?
CATX returned -29.11% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.